Enliven Therapeutics, Inc. (ELVN)
USD 15.56
(4.36%)
USD 15.56
(4.36%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -61.26 Million | -32.07 Million | -19.13 Million | -8.52 Million | -21.87 Million | -8.77 Million |
| Net Income | -71.58 Million | -37.66 Million | -24.74 Million | -18.96 Million | -23.46 Million | -11.33 Million |
| Depreciation & Amortization | 297 Thousand | 215 Thousand | 115 Thousand | 45 Thousand | 33 Thousand | - |
| Deferred income taxes | 2.25 Million | - | -3.8 Million | - | -215 Thousand | - |
| Stock-based compensation | 12.91 Million | 3.19 Million | 1.92 Million | 130 Thousand | 899 Thousand | 555 Thousand |
| Change in working capital | 1.4 Million | 438 Thousand | 3.56 Million | 583 Thousand | 673 Thousand | 1.23 Million |
| Other non-cash items | -6.54 Million | 1.74 Million | 3.8 Million | 9.67 Million | 196 Thousand | 848 Thousand |
| Investing Cash Flow | -148.41 Million | -612 Thousand | -191 Thousand | -461 Thousand | -24.06 Million | - |
| Investments in PPE | -149 Thousand | -612 Thousand | -191 Thousand | -461 Thousand | -140 Thousand | - |
| Acquisitions | - | 35 Million | - | - | - | - |
| Investment purchases | -268.26 Million | -35 Million | -47.55 Million | -64.2 Million | -23.92 Million | - |
| Sales/Maturities of investments | 120 Million | 41.87 Million | 45.93 Million | 47.5 Million | - | - |
| Other Investing Activities | -1.00 | -41.87 Million | 1.62 Million | 16.7 Million | - | - |
| Financing Cash Flow | 234.28 Million | -1.79 Million | -1.01 Million | 130.51 Million | 43.57 Million | 6.48 Million |
| Debt repayment | - | - | - | - | -1.99 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -226 Thousand | - | - | - |
| Common Stock Issuance | 161.2 Million | 591 Thousand | 690 Thousand | 140 Thousand | 45.57 Million | 6.48 Million |
| Other Financing Activities | 73.08 Million | -2.39 Million | -1.48 Million | 130.37 Million | - | 6.48 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -2.25 Million | 411 Thousand | 1.73 Million | 291 Thousand | 750 Thousand | 477 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 3.65 Million | 27 Thousand | 1.83 Million | 292 Thousand | -77 Thousand | 758 Thousand |
| Cash at beginning of period | 75.53 Million | 110.07 Million | 130.41 Million | 8.89 Million | 7.38 Million | 9.67 Million |
| Cash at end of period | 100.19 Million | 75.59 Million | 110.07 Million | 130.41 Million | 4.93 Million | 7.38 Million |
| Capital Expenditure | -149 Thousand | -612 Thousand | -191 Thousand | -461 Thousand | -140 Thousand | - |
| Effect of forex changes on cash | 54 Thousand | 74.2 Million | - | - | -88 Thousand | - |
| Net cash flow / Change in cash | 24.65 Million | -34.48 Million | -20.34 Million | 121.52 Million | -2.44 Million | -2.28 Million |
| Free Cash Flow | -61.41 Million | -32.68 Million | -19.32 Million | -8.99 Million | -22.01 Million | -8.77 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -19.95 Million | -22.73 Million | -19.37 Million | -71.58 Million | -20.76 Million | -16.72 Million |
| Depreciation & Amortization | 79 Thousand | 79 Thousand | 77 Thousand | 297 Thousand | 78 Thousand | 74 Thousand |
| Deferred income taxes | - | - | -4.17 Million | 2.25 Million | - | - |
| Stock-based compensation | 5.14 Million | 4.51 Million | 3.05 Million | 12.91 Million | 3.4 Million | 4.19 Million |
| Change in working capital | -4.38 Million | -4.63 Million | 5.46 Million | 1.4 Million | 3.15 Million | 1.23 Million |
| Other non-cash items | 5.58 Million | 1.93 Million | 2.46 Million | -6.54 Million | -1.75 Million | -831 Thousand |
| Investing Cash Flow | -33.66 Million | -17.88 Million | 38.68 Million | -148.41 Million | -35.54 Million | -151.51 Million |
| Investments in PPE | -2000.00 | -20 Thousand | -14 Thousand | -149 Thousand | -16 Thousand | -88 Thousand |
| Acquisitions | - | - | 40 Million | - | -40 Million | - |
| Investment purchases | -120.82 Million | -56.77 Million | -41.3 Million | -268.26 Million | -75.53 Million | -151.43 Million |
| Sales/Maturities of investments | 77.16 Million | 38.91 Million | 80 Million | 120 Million | 40 Million | - |
| Other Investing Activities | 10 Million | -17.86 Million | 38.7 Thousand | -1.00 | 40 Million | -151.43 Thousand |
| Financing Cash Flow | 1.8 Million | 90.27 Million | 90 Thousand | 234.28 Million | -425 Thousand | -2.82 Million |
| Debt repayment | - | - | -164.43 Thousand | - | - | -1535.00 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.8 Million | 90.27 Million | 90 Thousand | 161.2 Million | -425 Thousand | -1.5 Million |
| Other Financing Activities | 1806.00 | 270 Thousand | 90.00 | 73.08 Million | -453 Thousand | -1.31 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -1.6 Million | 2.15 Million | -961 Thousand | -2.25 Million | -1.59 Million | -188 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -2.78 Million | -6.79 Million | 6.42 Million | 3.65 Million | 4.74 Million | 1.42 Million |
| Cash at beginning of period | 149.21 Million | 100.19 Million | 73.84 Million | 75.53 Million | 125.76 Million | 292.15 Million |
| Cash at end of period | 96.92 Million | 149.21 Million | 100.19 Million | 100.19 Million | 73.9 Million | 125.76 Million |
| Capital Expenditure | -2000.00 | -20 Thousand | -14 Thousand | -149 Thousand | -16 Thousand | -88 Thousand |
| Effect of forex changes on cash | - | - | 54 Thousand | 54 Thousand | - | - |
| Net cash flow / Change in cash | -52.29 Million | 49.02 Million | 26.34 Million | 24.65 Million | -51.86 Million | -166.38 Million |
| Free Cash Flow | -20.43 Million | -23.38 Million | -12.49 Million | -61.41 Million | -15.91 Million | -12.13 Million |
NQMLF
BBROOM
4958
002961
OFX
SAM